Experts Debate Federal Legalization of Psychedelic Therapy at Harvard Law School Event

Psychedelic therapy and the prospects for federal legalization were debated at a Harvard Law School event hosted by the Petrie-Flom Center. Panelists discussed potential benefits for trauma and mood disorders alongside the need for FDA oversight and safeguards. David B. Yaden of Johns Hopkins highlighted classic psychedelics including psilocybin, LSD, and DMT, noting progress in clinical research and that psilocybin is in phase three out of four in its trials. Matthew “Whiz” Buckley described personal healing experiences, including using ibogaine, and linked those experiences to the mission of his nonprofit supporting veterans. The panel also emphasized caution and evidence requirements: Yaden warned against fast legalization without understanding individual variation in effects, while Holly Fernandez Lynch argued for holding psychedelic medicine to the same FDA standard as other medicines. Cat Packer stressed equity in reform, and Yaden identified funding as a major barrier, calling for larger government-supported trials to improve safety and effectiveness data.